Skip to main content
Log in

Population Pharmacokinetic Modeling of Steady State Carbamazepine Clearance in Children, Adolescents, and Adults

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

Carbamazepine (CBZ) clearance decreases from childhood to adulthood and the factors determining this change could include age, size, autoinduction, or maturational changes. This study aims to describe the population pharmacokinetics of CBZ in children and young adults and test the hypothesis that CBZ clearance correlates with weight, surface area, and age. CBZ therapeutic drug monitoring data (sparse data) were collected from child and adult epileptics, and rich data were obtained from a bioequivalence study of CBZ in young adults. Population pharmacokinetic analysis was performed using NONMEM V. Forward stepwise, multiple regression was performed on the covariates. Bootstrap validation was performed. A total of 946 observations from 91 subjects, ages 0.7–37 years, were collected and analyzed. A one-compartment, first-order absorption and elimination model, with exponential interindividual error and additive residual error models was developed. The population model was: Clearance (Lhr −1)=((2.24 · Surface area (m 2))+(0.047 · Dose (mg · kg −1)); Volume of distribution (L)=0.37 · weight (kg); Absorption rate constant=0.013 (hr −1). CBZ clearance increased with surface area and dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. R. H. Levy, W. H. Pitlick, A. S. Troupin, J. R. Green, and J. M. Neal. Pharmacokinetics of carbamazepine in normal man. Clin. Pharmacol. Ther. 17:657–668 (1975).

    Google Scholar 

  2. N. H. G. Holford. A size standard for pharmacokinetics. Clin. Pharmacokin. 30:329–332 (1996).

    Google Scholar 

  3. M. F. D. Iribarnegaray, D. S. Buelga, M. J. S. Sánchez, M. J. Otero, A. C. Falcaõ, and A. Domínguez-Gil. Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther. Drug. Monit. 19:132–139 (1997).

    Google Scholar 

  4. E. Yukawa and T. Aoyama. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J. Clin. Pharmacol. 36:752–759 (1996).

    Google Scholar 

  5. A. L. Gray, J. H. Botha, and R. Miller. A model for the determination of carbamazepine clearance in children on mono-and poly-therapy. Eur. J. Clin. Pharmacol. 54:359–362 (1998).

    Google Scholar 

  6. L. Sheiner and S. L. Beal. NONMEM V ed., NONMEM Project Group, San Francisco, 1994.

    Google Scholar 

  7. Microsoft. Fortran PowerStation 4.0, Microsoft Corporation, 1995.

  8. Microsoft. Excel SR-1, Microsoft Corporation, 1997.

  9. MathSoft. Axum 5.0B for Windows, MathSoft Inc., 1996.

  10. Stata Corporation. STATA for Windows 4.0 ed., Stata Corporation, College Station, TX77840, 1995.

  11. A. Boeckmann, L. Scheiner, and S. Beal. NONMEM Users Guide--Part V, University of California at San Francisco, 1994.

    Google Scholar 

  12. R. D. Mosteller. Simplified calculation of body-surface area. New Engl. J. Med. 1098 (1987).

  13. B. Sheiner. Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals. J. Pharmacokinet. Biopharm. 14:539–555 (1986).

    Google Scholar 

  14. J. Parke, N. H. G. Holford, and B. G. Charles. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Meth. Prog. Biomed. 59:19–20 (1999).

    Google Scholar 

  15. J. A. Lack and M. E. Stuart-Taylor. Calculation of drug dosage and body surface area of children. Br. J. Anaesth. 78:601–605 (1997).

    Google Scholar 

  16. K. Urata, S. Kawasaki, H. Matsunami, Y. Hashikura, T. Ikegami, S. Ishizone, Y. Momose, A. Komiyama, and M. Makuuchi. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 21:1317–1321 (1995).

    Google Scholar 

  17. J. Carles, J. El Kohen, D. Midy, J. Saric, and J. Videau. Appréciation du volume hépatique en fonction de la morphologie de l'individu. Bull. Assoc. Anatom. 77:9–13 (1993).

    Google Scholar 

  18. F. H. DeLand and W. A. North. Relationship between liver size and body size. Radiology 91:1195–1198 (1968).

    Google Scholar 

  19. N. M. Graves, R. C. Brundage, Y. Wen, G. Cascino, E. So, P. Ahman, J. Rarick, S. Krause, and I. E. Leppik. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 18:273–281 (1998).

    Google Scholar 

  20. L. Z. Benet and R. L. Williams. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In A. G. Gilman, T. W. Rall, A. S. Nies, and A. S. Taylor (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. International ed., 8th ed. McGraw-Hill, Singapore, 1991, pp. 1650–1736.

    Google Scholar 

  21. H. F. Hvidberg and M. Dam. Clinical pharmacokinetics of anticonvulsants. Clin. Pharmacokin. 1:161–188 (1976).

    Google Scholar 

  22. T. Tomson, J. O. Svensson, and P. Hilton-Brown. Relationship of intraindividual dose–plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther. Drug Monit. 11:533–539 (1989).

    Google Scholar 

  23. D. A. Graves, C. S. Locke, K. T. Muir, and R. P. Miller. The influence of assay variability on pharmacokinetic parameter estimation. J. Pharmacokin. Biopharm. 17: 571–592 (1989).

    Google Scholar 

  24. H. Sun, E. I. Ette, and T. M. Ludden. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data. J. Pharmacokin. Biopharm. 24:637–650 (1996).

    Google Scholar 

  25. D. B. White, C. A. Walawander, D. Y. Liu, and T. H. Grasela. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. J. Pharmacokin. Biopharm. 20:295–313 (1992).

    Google Scholar 

  26. M. K. Al-Banna, A. W. Kelman, and B. Whiting. Experimental design and efficient parameter estimation in population pharmacokinetics. J. Pharmacokin. Biopharm. 18:347–360 (1990).

    Google Scholar 

  27. E. I. Ette. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37:486–495 (1997).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reith, D.M., Hooper, W.D., Parke, J. et al. Population Pharmacokinetic Modeling of Steady State Carbamazepine Clearance in Children, Adolescents, and Adults. J Pharmacokinet Pharmacodyn 28, 79–92 (2001). https://doi.org/10.1023/A:1011569703060

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011569703060

Navigation